Earnings Highlights
EPS Actual
1.65
EPS Estimate
-0.10
Revenue Actual
Revenue Estimate
***
reporting data We deliver structured market intelligence based on earnings analysis and institutional trading patterns. vTv Therapeutics reported first-quarter 2026 earnings per share of $1.65, far exceeding the consensus estimate of -$0.0969 – a staggering positive surprise of 1,802.79%. The company posted zero revenue during the quarter. Despite the huge earnings beat, shares declined 3.01% in after-market trading, likely reflecting the one-time nature of the earnings driver.